Harvard Bioscience - Comparative Multiple Analysis

Harvard Bioscience (Comparative Multiple Analysis)


Notes on the Comparative Multiple Analysis of Harvard Bioscience

WikiWealth compares Harvard Bioscience's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with Harvard Bioscience's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for Harvard Bioscience.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to Harvard Bioscience's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for Harvard Bioscience's Analysis

How does this work? The Comparative Investment Analysis determines the value of Harvard Bioscience by comparing Harvard Bioscience financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of Harvard Bioscience.

See the Harvard Bioscience cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in Harvard Bioscience.

Also, see the Harvard Bioscience's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and Harvard Bioscience's valuation conclusion for a quick summary.